CEO Robert Connelly was paid $1,887,660 in fiscal year 2025, ↓ down 7.3% from fiscal year 2024, the 1st percentile of its disclosed peer group (SEC filing 0001601485-26-000061 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$1,887,660 ↓ Robert Connelly total, FY2025 | 1st CEO pay percentile vs peers | — CEO-to-median pay ratio | — Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
ELTX's next annual pay disclosure, estimated April 9, 2028.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Robert Connelly | $632,700 | $0 | $0 | $906,960 | $348,000 | $0 | $0 | $1,887,660 |
| President, Chief Executive Officer, and Director | ||||||||
| Preetam Shah | 350,612 | 0 | 0 | 796,143 | 201,600 | 0 | 29,331 | 1,377,686 |
| Chief Strategy and Financial Officer and Treasurer | ||||||||
| Christopher Haqq | 528,100 | 0 | 0 | 328,176 | 221,900 | 0 | 0 | 1,078,176 |
| Executive Vice President, Head of Research and Development and Chief Medical Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Robert Connelly | $1,887,660 | $2,036,441 | $678,300 | ↓ −148,781 |
| Preetam Shah | 1,377,686 | — | — | — |
| Christopher Haqq | 1,078,176 | 926,452 | 673,821 | ↑ +151,724 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read Elicio Therapeutics, Inc.'s Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper ELTX reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
Get the Elicio Therapeutics, Inc. Peer Teardown Report
$1,887,660 Robert Connelly total, FY2025
$199
The free page is the headline. The teardown reads every company in the disclosed peer group on its own numbers.
Data as of October 9, 2026 · Source: 0001601485-26-000061 · Velarion Executive Compensation Database, deposited on Zenodo (doi:10.5281/zenodo.22283855).
Reports for ELTX
Every report below is generated from the same filings as the free brief above, at the moment of purchase. What each one adds:
Order ELTX
Pick the report, add the email the receipt and the PDF go to, and pay by card on Stripe.
How we handle your data → Privacy
The list of companies that name ELTX as a peer is temporarily unavailable — recheck shortly.
Get the Elicio Therapeutics, Inc. Executive Compensation Report
$1,500
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| Allen R. Nissenson, M.D | Independent Director | $90,258 |
| Carol Ashe | Independent Director | $100,258 |
| Jay R. Venkatesan, M.D | Director | — |
| Julian Adams, Ph.D | Chair of the Board | $120,758 |
| Karen J. Wilson | Independent Director | — |
| Robert R. Ruffolo, Jr., Ph.D., FCPP | Director | — |
| Yekaterina (Katie) Chudnovsky | Director | $77,758 |
No insider equity transactions reported since the proxy statement.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Robert Connelly | Option | 45,800 | 5.03 | — |
| Christopher Haqq | Option | 44,000 | 8.92 | — |
| Christopher Haqq | Option | 15,275 | 4.5 | — |
| Robert Connelly | Option | 121,600 | 8.92 | — |
| Robert Connelly | Option | 121,950 | 4.5 | — |
| Preetam Shah | Option | 191,624 | 4.98 | — |
| Christopher Haqq | Option | 14,100 | 5.03 | — |
We seek to ensure the total compensation paid to our executive officers is reasonable and competitive. Compensation of our executives is structured around the achievement of individual performance and near-term corporate targets as well as long-term business objectives.
| CEO STI target (% of salary) | 55% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon plc |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2025 | 2025-05-19 | — | — | — | — | — |
| 2024 | 2024-11-21 | — | — | — | — | — |
| 2022 | 2022-06-09 | — | — | — | — | — |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2025 | 2025-05-19 | —a |
| 2024 | 2024-11-21 | —b |
| 2022 | 2022-06-09 | —c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Julian Adams, Ph.DIndependent · Board Chair · Nominating and Corporate Governance | $83,000 | — | $37,758 | — | — | $120,758 |
| Carol AsheIndependent · Audit · Compensation (Chair) · Nominating and Corporate Governance | 62,500 | — | 37,758 | — | — | 100,258 |
| Karen WilsonIndependent · Audit (Chair) · Nominating and Corporate Governance | 60,000 | — | 37,758 | — | — | 97,758 |
| Allen R. Nissenson, M.DIndependent · Audit · Compensation · Nominating and Corporate Governance (Chair) | 52,500 | — | 37,758 | — | — | 90,258 |
| Robert R. Ruffolo Jr., Ph.DIndependent · Compensation | 45,000 | — | 37,758 | — | — | 82,758 |
| Yekaterina (Katie) ChudnovskyNot independent | 40,000 | — | 37,758 | — | — | 77,758 |
| Jay Venkatesan, M.DIndependent | 40,000 | — | 37,758 | — | — | 77,758 |
| Robert ConnellyEmployee director | — | — | — | — | — | 0 |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 12,000 / 10,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $383,000 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $383,000 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Elicio Therapeutics, Inc. | 2025 | Robert Connelly | $632,700 | $0 | $906,960 | $348,000 | $1,887,660 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Robert Connelly | DEF 14A | 2026-10-09 | 0001601485-26-000061 | Section “Summary Compensation Table” · page 34. As printed: 1,887,660. Filing ↗machine: r3 · c21 · span 374718–374727 |
| 2 | Section 01, Preetam Shah | DEF 14A | 2026-10-09 | 0001601485-26-000061 | Section “Summary Compensation Table” · page 34. As printed: 1,377,686. Filing ↗machine: r5 · c21 · span 380412–380421 |
| 3 | Section 01, Christopher Haqq | DEF 14A | 2026-10-09 | 0001601485-26-000061 | Section “Summary Compensation Table” · page 34. As printed: 1,078,176. Filing ↗machine: r7 · c21 · span 385980–385989 |
| 4 | Section 08, Julian Adams, Ph.D | DEF 14A | 2026-10-09 | 0001601485-26-000061 | Section “Director Compensation”. As printed: 120,758. Filing ↗machine: span 481910–482124 |
| 5 | Section 08, Carol Ashe | DEF 14A | 2026-10-09 | 0001601485-26-000061 | Section “Director Compensation”. As printed: 100,258. Filing ↗machine: span 483435–483680 |
| 6 | Section 08, Karen Wilson | DEF 14A | 2026-10-09 | 0001601485-26-000061 | Section “Director Compensation”. As printed: 97,758. Filing ↗machine: span 489955–490199 |
| 7 | Section 08, Allen R. Nissenson, M.D | DEF 14A | 2026-10-09 | 0001601485-26-000061 | Section “Director Compensation”. As printed: 90,258. Filing ↗machine: span 485064–485308 |
| 8 | Section 08, Robert R. Ruffolo Jr., Ph.D | DEF 14A | 2026-10-09 | 0001601485-26-000061 | Section “Director Compensation”. As printed: 82,758. Filing ↗machine: span 488336–488580 |
| 9 | Section 08, Yekaterina (Katie) Chudnovsky | DEF 14A | 2026-10-09 | 0001601485-26-000061 | Section “Director Compensation”. As printed: 77,758. Filing ↗machine: span 486700–486944 |
| 10 | Section 08, Jay Venkatesan, M.D | DEF 14A | 2026-10-09 | 0001601485-26-000061 | Section “Director Compensation”. As printed: 77,758. Filing ↗machine: span 491742–492018 |
| 11 | Section 08, Robert Connelly | DEF 14A | 2026-10-09 | 0001601485-26-000061 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 12 | Section 06, 2025 vote | Form 8-K | 2025-05-20 | 0001601485-25-000076 | Item 5.07 · say-on-pay result. As reported: —. Filing ↗ |
| 13 | Section 06, 2024 vote | Form 8-K | 2024-11-21 | 0001601485-24-000083 | Item 5.07 · say-on-pay result. As reported: —. Filing ↗ |
| 14 | Section 06, 2022 vote | Form 8-K | 2022-06-14 | 0001601485-22-000055 | Item 5.07 · say-on-pay result. As reported: —. Filing ↗ |
| 15 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 16 | Section 09b board cost (computed) | Computed | — | — | Cash 383,000 + equity 0 + all other 0 = 383,000, summed across the director compensation table rows.machine: formula: Σ = 383,000 |
| 17 | Elicio Therapeutics, Inc. (subject), Section 10b CEO total | DEF 14A | 2026-10-09 | 0001601485-26-000061 | CEO total compensation as printed in Elicio Therapeutics, Inc.'s own proxy. As printed: 1,887,660. Filing ↗machine: r3 · c21 · span 374718–374727 |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.
Get the Elicio Therapeutics, Inc. Executive Compensation Report
$1,500